KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation and Depletion (2018 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Depreciation and Depletion data on record, last reported at $130000.0 in Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 11.56% year-over-year to $130000.0; the TTM value through Dec 2025 reached $548000.0, down 14.24%, while the annual FY2025 figure was $548000.0, 14.38% down from the prior year.
  • Depreciation and Depletion reached $130000.0 in Q4 2025 per AQST's latest filing, down from $139000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $743000.0 in Q1 2021 and bottomed at $130000.0 in Q4 2025.
  • Average Depreciation and Depletion over 5 years is $375800.0, with a median of $268000.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: increased 14.24% in 2023, then crashed 62.6% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $717000.0 in 2021, then plummeted by 52.02% to $344000.0 in 2022, then rose by 14.24% to $393000.0 in 2023, then tumbled by 62.6% to $147000.0 in 2024, then fell by 11.56% to $130000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $130000.0 in Q4 2025, $139000.0 in Q3 2025, and $140000.0 in Q2 2025.